Abstract:Objective To observe the efficacy,side effect and health economics values of the therapy of antidepressants combining atypical antipsychotics with different administration lengths,on nonpsychotic symptom,treatment-resistant depression. Methods 99 patients out of the randomized 4 groups of patients completed one year follow-up study.The 4 groups are the group of single therapy of fluoxetine(27 patients),the group of therapy of fluoxetine combining 1~2 months administration of olanzapine(28 patients),the group of therapy of fluoxetine combining 4~6 months administration of olanzapine(29 patients) and the group of therapy of fluoxetine combining 12 months administration of olanzapine(15 patients).At the starting point,measure of all patients in the four groups the HAMD,SDSS,weight and annual income ete at the end of 1 year follow-up study,measure of those patients the HAMD,weight.TESS and income of the past year,working hours,recurrent frequency and therapeutic sosts etc.The decreased scores of HAMD tests and the cure rates are used to evaluate the efficacy,the TESS scores and weight records are used to evaluate the side effect,and the working hours,annual income and therapeutic costs are used to evaluate the health economics values. Results All patients of the four groups improved at different degree comparing to their pre-therapeutic period.The group of therapy of fluoxetine combining 4~6 months administration of olanzapine and the group of therapy of fluoxetine combining 12 months administration of olanzapine were improved more significantly than the other two groups.No patients in the four groups showed severe side effects,but patients of the three groups of combination therapy had weight increase at different degree comparing with the fluoxetine single using group.In terms of annual income,working hours and recurrent frequency,the 4~6 months olanzapine combination group and the 12 months olanzapine combination group are superior to the other two groups.The 4~6 months olanzapine combination group is at lower therapeutic cost than the 12 months olanzapine combination group. Conclusions Therapy of olanzapine,the atypical antipsychotics,combining fluoxetine on nonpsychotic symptom,treatment-resistant depression has definite curative effect and less side effects.The most appropricate administration length of olanzapine in the combination is 4~6 months..

Randomized Double-Blind Control Study of Olanzapine Augmented with Fluoxetine for Schizophrenia with Depression Symptom

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

A controlled trial of olanzapine and fluoxetine in treatment of negative symptoms of schizophrenia

Olanzapine Versus Lithium in the Acute Treatment of Bipolar Mania: A Double-Blind, Randomized, Controlled Trial

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

A study on efficacy and safety of fluoxetine combined with olanzapine in the treatment of major depression

The efficacy and safety of olanzapine combined with fluoxetine in the treatment of negative symptoms of schizophrenia:a systematic review

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia A Randomized, Double-Blind, Multicenter Study

A study of olanzapine and fluoxetine combination therapy on nonpsychotic symptom,treatment-resistant depression

Randomised, Double-Blind, Placebo-Controlled Study of Olanzapine in Patients with Bipolar I Depression

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Effect observation of escitalopram combination with ziprasidone in the treatment of treatment-resistant depression

The Efficacy and Adverse Effects of Haloperidol and Olanzapine: a Randomized Controlled Study.

Efficacy and safety of low-dose amisulpride versus olanzapine-fluoxetine combination in post-schizophrenic depression: A randomized controlled trial

A Study of the Efficacy and Safety of Olanzapine in the Treatment of Schizophrenia

Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial

Control study of mirtazapine and fluoxetine in therapy of depression

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

The Effect of Negative Symptoms of Chronic Schizophrenia with Clozapine Combination Fluoxetine